Sunshine Biopharma, Inc.

NasdaqCM:SBFM Stock Report

Market Cap: US$4.9m

Sunshine Biopharma Management

Management criteria checks 3/4

Sunshine Biopharma's CEO is Steve Slilaty, appointed in Oct 2009, has a tenure of 15.08 years. total yearly compensation is $640.00K, comprised of 59.1% salary and 40.9% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth $148.81. The average tenure of the management team and the board of directors is 8 years and 3.1 years respectively.

Key information

Steve Slilaty

Chief executive officer

US$640.0k

Total compensation

CEO salary percentage59.1%
CEO tenure15.1yrs
CEO ownership0.003%
Management average tenure8yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Mar 14
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Jan 29
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sep 12
Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sunshine Biopharma acquires Nora Pharma for C$30M

Oct 20

We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Aug 08
We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Sunshine Biopharma reports 1H results

Aug 04

Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs

Apr 17

CEO Compensation Analysis

How has Steve Slilaty's remuneration changed compared to Sunshine Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$4m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$640kUS$378k

-US$5m

Sep 30 2023n/an/a

-US$27m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$430kUS$360k

-US$27m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

-US$5m

Mar 31 2022n/an/a

-US$7m

Dec 31 2021US$462kUS$156k

-US$12m

Sep 30 2021n/an/a

-US$14m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020US$227kUS$177k

-US$3m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$2m

Mar 31 2020n/an/a

-US$972k

Dec 31 2019US$96kUS$28k

-US$1m

Sep 30 2019n/an/a

-US$1m

Jun 30 2019n/an/a

-US$2m

Mar 31 2019n/an/a

-US$2m

Dec 31 2018US$285kUS$85k

-US$2m

Sep 30 2018n/an/a

-US$2m

Jun 30 2018n/an/a

-US$1m

Mar 31 2018n/an/a

-US$1m

Dec 31 2017US$268kUS$156k

-US$1m

Compensation vs Market: Steve's total compensation ($USD640.00K) is about average for companies of similar size in the US market ($USD647.72K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

CEO

Steve Slilaty (72 yo)

15.1yrs

Tenure

US$640,000

Compensation

Dr. Steve N. Slilaty, Ph.D. is CEO & Chairman of Sunshine Biopharma, Inc. from October 15, 2009 and serves as President. Dr. Slilaty joined the Sunshine Biopharma, Inc. on October 15, 2009. He serves as th...

Leadership Team

NamePositionTenureCompensationOwnership
Steve Slilaty
Chairman15.1yrsUS$640.00k0.0031%
$ 148.8
Camille Sebaaly
CFO & Secretary15.1yrsUS$695.00k0.0030%
$ 146.4
Abderrazzak Merzouki
Chief Science Officer & Directorless than a yearUS$340.00k0.0029%
$ 143.9
Malek Chamoun
Chief Development Officerless than a yearno data0.093%
$ 4.5k
Robert Ferreira
President of Sunshine Bio Investments Incno datano datano data

8.0yrs

Average Tenure

62yo

Average Age

Experienced Management: SBFM's management team is seasoned and experienced (8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Steve Slilaty
Chairman15.1yrsUS$640.00k0.0031%
$ 148.8
Abderrazzak Merzouki
Chief Science Officer & Director8.8yrsUS$340.00k0.0029%
$ 143.9
David Natan
Independent Director2.8yrsUS$80.00kno data
Rabi Kiderchah
Independent Director3.1yrsUS$80.00k0.000050%
$ 2.4
Andrew Keller
Independent Director2.8yrsUS$80.00kno data

3.1yrs

Average Tenure

70yo

Average Age

Experienced Board: SBFM's board of directors are considered experienced (3.1 years average tenure).